MarketBeat
05 Nov 2026, 09:17 UTC · 9h ago
What Veracyte (VCYT) Said on Its Q3 Earnings Call
Impact · against what's priced in
Veracyte's outlook suggests a growth trajectory lower than what the current price requires, as 2027 revenue growth is projected in the mid-single digits compared to the roughly 9% implied by the reverse DCF. The deceleration of Decipher Prostate volumes further undermines the core testing growth the market expects, while the impact of new tests remains modest.
- VCYT−0.40
Challenges what's priced in
- The price assumes
A revenue growth deceleration to roughly 9% annually over the next decade
The company provided a preliminary 2027 outlook of mid-single-digit revenue growth, which is a step down from the 8.9% - 9% annual growth the current price already assumes.
What VCYT's price assumes · Sep 24
